FM
fazen.markets
healthcare·esfritzh

Protagenic Raises $1.5M for PT00114 Anxiety Trial

0h ago|5 min readStandard
FM

Fazen Markets

Source: SEC EDGAR

Written by AI from a primary source ·

protagenic-therapeuticsptix-stockpt00114generalized-anxiety-disorderprivate-placement
Sponsoredby Fazen Capital

AiX — Free Expert Advisor

Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.

Myfxbook verified No subscription XAUUSD M15
Get Free EA

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.

Key Takeaways

  • 1Protagenic has funded only the next step: an IND submission and first U.S. dosing in GAD, with the rest contingent on warrant exercises and further raises.

Partner

Trade the Markets Discussed in This Article

Regulated Broker Competitive Spreads

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Protagenic Therapeutics, Inc. (OTCQB: PTIX) announced on 11 November 2026 a private placement that provides $1.5 million in upfront gross proceeds, with up to $3.5 million more if two series of milestone-linked warrants are exercised in full — a total potential of $5 million before placement agent fees and offering expenses. Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as sole placement agent. The company said it will use the proceeds to complete IND-enabling work for PT00114, its lead neuropeptide asset, and to start a Phase 1/2a trial in Generalized Anxiety Disorder.

Context — why this matters now

The financing lands two months after Protagenic received written responses from the U.S. Food and Drug Administration to its Type B pre-IND meeting request for PT00114 in GAD. According to the company, the FDA identified no deficiencies that would preclude an IND submission. That is the comparable the company itself supplies: an earlier regulatory checkpoint that cleared a path rather than closing one.

Since August 2026, Protagenic has been folding the FDA's requests into its submission while completing chemistry, manufacturing and controls work. The company said that work included refined CMC specifications and expanded dose cohorts. It also finalized the Phase 1/2a study design.

The trigger for raising capital now is that CMC and IND-enabling activities consume cash before any patient is dosed. The company said the proceeds are intended to carry PT00114 through IND-enabling work, trial initiation, and into working capital and general corporate purposes.

Protagenic is a clinical-stage company with no approved product. Its shares trade on the OTCQB venture tier rather than a national exchange, and the company acknowledged in its own risk language that its common stock may be considered a penny stock.

The U.S. program rests on two completed Phase 1 studies run outside the United States: a single ascending dose study in May 2024 and a multiple ascending dose study whose positive topline safety results the company reported in December 2025.

Data — what the numbers show

The headline figures are small in absolute terms but structured in two tranches. The first is $1.5 million of upfront gross proceeds. The second is up to $3.5 million tied to the exercise of two series of milestone-linked warrants.

ElementAmount
Upfront gross proceeds$1.5 million
Additional, if warrants exercised in fullUp to $3.5 million
Total potential gross proceedsUp to $5 million
Placement agentBrookline Capital Markets

All figures are gross. The company said placement agent fees and offering expenses are deducted from those amounts, and it did not disclose the fee rate, the warrant strike prices, the milestones that trigger exercisability, or the number of shares sold.

On timing, the company targets an IND submission in late Q1 2027 and first patient dosing in Q2 2027, which it said is consistent with the first-half 2027 timeline previously announced. Topline safety data is expected in 2H 2027 and exploratory efficacy data in 1H 2028.

The prior clinical dataset is the only efficacy-adjacent benchmark the company cites: in the multiple ascending dose study, PT00114 was well tolerated across all dose levels studied, and no serious adverse events were observed. No efficacy readout from those studies was disclosed.

Analysis — what it means for markets, sectors and tickers

The financing structure tells the story for anyone tracking micro-cap biotech. An upfront tranche of $1.5 million is a bridge, not a runway. The $3.5 million second tranche only arrives if warrant milestones are hit, which means the company's near-term cash position depends partly on its own clinical progress and partly on holders choosing to exercise.

For the anxiety and stress-related neuropsychiatric space, PT00114 is described as a first-in-class investigational neuropeptide and a synthetic analog of teneurin C-terminal associated peptide, a naturally occurring brain peptide thought to help regulate the stress response. The company is positioning it first in GAD, with potential future applications in PTSD and treatment-resistant depression.

The Phase 1/2a design is the efficiency argument. Ascending-dose cohorts evaluate safety, tolerability and pharmacokinetics, then a GAD patient cohort adds exploratory efficacy measures, including change from baseline in Hamilton Anxiety Rating Scale total score. The company said the intent is to generate safety data and an early efficacy signal in a single study.

The counter-argument sits in the company's own filings language. FDA pre-IND advice is non-binding; the agency can request more information, impose a clinical hold, or delay the program. Exploratory endpoints in a small early cohort are not predictive of later results. Protagenic also flagged its ability to continue as a going concern and the availability and terms of additional financing.

Positioning follows from that. The holder base is dominated by investors willing to underwrite binary clinical and regulatory risk at OTC scale. President Bill Nichols Jr. said the company continues to pursue strategic options and additional capital so priority R&D work is well resourced — a signal that this placement is not the end of the funding plan.

Outlook — what to watch next

The near-term catalyst is the IND submission, targeted for late Q1 2027. Before that, the CMC package must hold up, since the company said refined specifications and expanded dose cohorts are part of the pending work.

The second catalyst is first patient dosing, targeted for Q2 2027 and contingent on FDA review of the IND. A clinical hold or an information request at that stage would push the timeline.

Data milestones follow: topline safety data expected in 2H 2027, then exploratory efficacy data in 1H 2028. Because the trial pairs dose escalation with a GAD patient cohort, the safety readout and the efficacy readout are separate events rather than a single binary.

The variable investors cannot see is warrant exercise. Protagenic did not disclose the strike prices or the specific milestones, so the path to the full $5 million is opaque. Watch for a registration statement covering resale of the shares and the shares underlying the pre-funded and common warrants, which the company agreed to file under a registration rights agreement.

Frequently Asked Questions

What does this private placement mean for retail investors in PTIX?

The financing adds $1.5 million in gross upfront cash and a potential $3.5 million more, but it also adds dilution through shares, pre-funded warrants and common warrants. Protagenic agreed to register the resale of those securities, so newly issued shares can become freely tradable. The company has no approved product and flagged going-concern risk, so the equity remains a clinical-stage, binary-risk holding rather than a revenue-backed one.

What is PT00114 and why is the GAD trial the key event?

PT00114 is Protagenic's lead clinical asset, described as a first-in-class investigational neuropeptide and a synthetic analog of teneurin C-terminal associated peptide, a naturally occurring brain peptide thought to help regulate the stress response. The planned Phase 1/2a study would be its first U.S. trial. It is designed to produce safety, tolerability and pharmacokinetic data plus an exploratory efficacy signal in GAD patients, including HAM-A score change.

Why did the company structure the raise in two tranches?

Splitting the financing into $1.5 million upfront and up to $3.5 million on warrant exercise limits the immediate share issuance while keeping capital available if the program advances. The company did not disclose the warrant strike prices or the milestones that unlock exercise, so the timing and size of the second tranche depend on terms investors have not seen. The proceeds are earmarked for IND-enabling activities and trial initiation.

Bottom Line

Protagenic has funded only the next step: an IND submission and first U.S. dosing in GAD, with the rest contingent on warrant exercises and further raises.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.

Sponsored — AiX

Trade XAUUSD on autopilot — free Expert Advisor

AiX is our free MetaTrader 5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.

Get Free EA

PartnerPosition yourself for the macro moves discussed above

Start Trading
Share

Stay informed

Get market analysis delivered to your inbox.

Join 18,500+ investors

Sponsored

Ready to trade the markets?

Open a demo account in 30 seconds. No deposit required.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Related